VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Key facts
| Status | Awarded |
|---|---|
| Estimated value | $45,192,122 |
| Submission deadline | Deadline not published |
| Published | Sep 15, 2023 |
| Buyer | Office of Assistant Secretary for Preparedness and Response |
| Country | United States · PA |
| CPV code | NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13 |
| Source | USAspending.gov Federal Contract Awards ↗ |
- Status
- Awarded
- Estimated value
- $45,192,122
- Submission deadline
- Deadline not published
- Published
- Sep 15, 2023
- Country
- United States
- CPV code
- NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13
- Source
- USAspending.gov Federal Contract Awards
Contract outcome & evergreen alternatives
This notice is no longer open for submissions. The original remains available for reference.
| Awarded supplier / winner | Registration / LEI number | Country | Awarded contract amount | Award date |
|---|---|---|---|---|
| BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | US-UEI: UA43HWRNXFS3 | United States | $45,192,122 | Sep 15, 2023 |
Checked:
The original notice takes precedence. Its status and conditions can change after collection.
Description
VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Awarding Agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response.
NAICS 541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
PSC AN13: HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT.
Period of Performance: 2023-09-15 to 2027-12-31.